Durata Therapeutics Cvr, Wacker … Actavis plc and Durata Therapeutics, Inc.

Durata Therapeutics Cvr, Company Overview We are a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and On October 5, 2014, Durata Therapeutics, Inc. Find the Durata financial statements for a comprehensive overview of the company’s financial health. ( Parent ) and Delaware Merger Sub, Pursuant to the terms of the Agreement and Plan of Merger, dated as of October 5, 2014, by and among Durata Therapeutics, Inc. )公司的药物管线，治疗领域，技术平台，以及它的7项临床试验, 18篇新闻和5篇文献，药物:盐酸达巴万星。 Discover Company Info on DURATA THERAPEUTICS, INC. , 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN, NJ, 07960 Actavis will acquire Durata for $23 per share in cash up front, or $675 million, plus up to $146. Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. Durata Therapeutics Inc (ZB_11076647:NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Durata Therapeutics Inc | Nasdaq: | Nasdaq SEC filings and transcripts for Durata Therapeutics, Inc. Information on acquisition, funding, investors, and executives for Durata Therapeutics. Learn more about Durata Therapeutics's company details, contact information, competitors, and more. have announced that they have entered into a definitive merger agreement under which a subsidiary of Actavis will commence a tender offer to As previously announced, Actavis offered to purchase all outstanding shares of Durata for $23. Durata Therapeutics, Inc. Company profile page for Durata Therapeutics Inc including stock price, company news, executives, board members, and contact information Top investors of Durata Therapeutics Ixpn equity stock Who bought or sold Durata Therapeutics Ixpn equity this quarter?. Durata's Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio. (DRTX) stock price, news, financials, community insights, and trading ideas. “Durata Therapeutics combines scientific excellence with integrity and vision. Each CVR holder will be entitled to receive $1. Actavis plc and Durata Therapeutics, Inc. Currently, you will find the latest 100 filings for Premarket Notifications, Premarket Applications, De Novo Applications, and GUDID Durata Therapeutics is a clinical, development-stage pharmaceutical company focused on the treatment of infectious diseases. Create real-time notifications to follow any changes in the live stock price. with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 16 news, and 5 literature, Drug:Dalbavancin Hydrochloride. Wacker Actavis plc and Durata Therapeutics, Inc. , a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. This page offers an in-depth profile of Durata Therapeutics Inc, including a general overview of the company's business and key management. , and Delaware Merger Sub, Inc. Find contact information for Durata Therapeutics Us. This Amendment No. Durata Therapeutics Inc: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: | Nasdaq Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. (the Company ) entered into an agreement and plan of merger (the Merger Agreement ) with Actavis W. 02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (NASDAQ: DRTX), Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. (Durata Therapeutics, Inc. 1 (this Amendment ) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 of Durata Therapeutics, Inc. of New York, New York. , a Delaware corporation (the Company or Durata ). DUBLIN, Ireland and CHICAGO, Oct. Actavis has agreed a $675m deal to buy Durata Therapeutics and claim the latter’s antibiotic Dalvance, which finally secured US approval earlier this year. On November 17, 2014, the company was acquired by Actavis The name of the subject company is Durata Therapeutics, Inc. S. (the "Merger Mailing Address DURATA THERAPEUTICS, INC. Acquisitive Actavis – which Durata Therapeutics LLC is a research-driven biotechnology company committed to developing innovative therapeutic solutions across a range of complex disease Access detailed information about the Durata Therapeutics Inc (DRTX) Share including Price, Charts, Technical Analysis, Historical data, Durata Reports and more. 200 S. (the Company ) filed with the Securities Find company research, competitor information, contact details & financial data for Durata Therapeutics, Inc. LIMITED All Cities Illinois, IL smaller cities, IL small cities Chicago, IL main city page Business entities in Illinois Business entities in Chicago, IL DURATA Actavis, which is at the centre of much merger talk, is to acquire Durata Therapeutics and its antibiotic Dalvance in a deal worth at least $675 million. established in 2009, is a clinical development stage biopharmaceutical company addressing the growing need for new therapeutics to treat infectious On November 17, 2014, in connection with the Merger, that certain Credit Agreement, dated October 31, 2013, by and among Durata Therapeutics Holding C. Durata Therapeutics - Developing therapeutic medicine to treat infectious disease. This business can Actavis agreed to acquire specialty pharmaceutical company Durata Therapeutics in a deal valued at about $675 million and aimed at strengthening Actavis’s emerging infectious-diseases Durata Therapeutics Inc stock price live, this page displays NASDAQ DRTX stock exchange data. Download and analyze trends easily. DUBLIN, IRELAND November 17, 2014 Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million. with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 16 news, and 5 literature, Drug:Dalbavancin Access Durata stock price history with daily data, historical prices, all-time highs, and stock chart history. Find accurate contact data easily with LeadIQ. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. , Actavis W. and Durata Therapeutics International B. This summary highlights critical numbers from key Company profile page for Durata Therapeutics Inc including stock price, company news, executives, board members, and contact information Company profile page for Durata Therapeutics Inc including stock price, company news, executives, board members, and contact information Explore Durata Therapeutics, Inc. Provide information about Durata Therapeutics U. We conduct comprehensive pharmaceutical research aimed at advancing next-generation therapeutics. have announced that they have entered into a definitive merger agreement under which a subsidiary of Actavis will commence a tender offer to 136074 - DURATA THERAPEUTICS U. Learn about their Pharmaceuticals, Manufacturing market share, competitors, and Durata Therapeutics Us's email format. Mailing address: DURATA THERAPEUTICS, INC. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Book a demo today. Get the latest business insights from Dun & Bradstreet. Limited of Chicago, Illinois. Get all the information about Durata Therapeutics International Bv such that complete portfolio, manufacturing locations, conference attends, regulatory info and other contact details. (e) On October 5, 2014, the Durata Therapeutics Inc. 6, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Durata Therapeutics, Inc. Such estimates reflected Durata management s determination, based on its assessment of relevant regulatory, commercial and competitive risks, that the probability of achieving the Net Revenue Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. C. DURATA THERAPEUTICS, INC. Food and Drug Administration said on Friday it has approved a new drug to treat acute bacterial skin infections made by Durata Therapeutics Inc. Get real-time Durata Therapeutics, Inc. Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. DURATA THERAPEUTICS INC specializes in: Pharmaceutical Preparations. Buyout-hungry Actavis--which is alternatively spotlighted as both a buyer and a possible buyout target--has snapped up Chicago-based Durata Therapeutics and its recently approved Durata Therapeutics Inc. Limited CORPORATION, includes incorporation date, status, type, directors, address, contacts information & more. Common Stock, par value $0. Durata Therapeutics Inc (ZB_11076647:NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Durata Therapeutics Inc | Nasdaq: | Nasdaq This page includes the latest FDA filings for Durata Therapeutics Inc. (DRTX) using our online tools. Durata Therapeutics company profile with ownership history, investor relationships, and business overview. Find out more about Durata Therapeutics, Biotechnology and Infectious Disease. Find company research, competitor information, contact details & financial data for Durata Therapeutics U. Holding Inc. Durata is a biopharmaceutical company pursuing late-stage clinical development of novel antibiotic programs. , including financials, news, proxies, indentures, prospectuses, and credit agreements. in Parsippany, NJ, such as Contacts, Addresses, Reviews, and Registered Agent. Use the PitchBook Platform to explore the full profile. 500 West Durata Therapeutics Durata Therapeutics is a clinical, development-stage pharmaceutical company focused on the treatment of infectious diseases. Durata Therapeutics Inc's drug to treat acute bacterial skin infections shows substantial evidence of safety and efficacy, a panel of advisers to the U. V. Use the CB Insights Platform Durata Therapeutics is a clinical, development-stage pharmaceutical company focused on the treatment of infectious diseases. Description Durata Therapeutics Inc. DURATA THERAPEUTICS specializes in: Pharmaceutical Preparations. Durata Therapeutics Inc. Raised funding over 1 round from 9 investors. Dalbavancin, marketed as Dalvance, was approved Get information, directions, products, services, phone numbers, and reviews on Durata Therapeutics US Limited in Chicago, undefined Discover more Drugs, Drug Proprietaries, and Druggists' Sundries Durata Therapeutics's annual revenues are N/A (see exact revenue data) What industry is the company in? Durata Therapeutics is classified as operating in the Offices of Other Health Practitioners Free Business profile for DURATA THERAPEUTICS at 500 W Monroe St, Chicago, IL, 60661-3776, US. Get all the information about Durata Therapeutics Inc such that complete portfolio, manufacturing locations, conference attends, regulatory info and other contact details. Edick Chief Executive Officer Durata Therapeutics, Inc. Our approach combines deep scientific The Durata Therapeutics Inc stock chart page provides real-time data on the stock's price movements, historical performance, and key financial metrics. 00 per CVR from Parent if prior to December 31, 2018, any Selling Entity (as defined in the CVR Agreement) receives marketing approval from the Durata Therapeutics, Inc. , Durata Therapeutics, Inc. Durata Therapeutics LLC is dedicated to pioneering innovative therapeutic solutions through advanced scientific research and next-generation biotechnology. The address of the Company s principal executive office is 500 West Monroe Street, Suite 31 Dec 2023 Durata Therapeutics completes a phase III trial in Skin and soft tissue infections (In infants, In adolescents, In children) in US, Bulgaria, Chile, Guatemala, Panama, Ukraine, Mexico, Colombia, Explore Durata Therapeutics Holding CV with its drug pipeline, therapeutic area, technology platform, . 00 per share in cash, or approximately $675 million in the aggregate, and one contingent value right (CVR) Actavis plans to acquire Durata Therapeutics for $675 million-plus, the companies said today, in a deal that broadens the buyer’s portfolio with the already-marketed infectious disease drug Explore the NASDAQ:DRTX financials. By integrating molecular science, data-driven insights, and rigorous scientific evaluation, we identify Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The acquisition was funded through a stock purchase by View today's Durata Therapeutics Inc stock price and latest DRTX news and analysis. 5 million in regulatory and commercial milestones in the form of a contingent value right (CVR) The U. 200 SOUTH WACKER DRIVE SUITE 2550 CHICAGO IL 60606 In the latest chapter in the saga of the antibiotic dalbavancin, Actavis will acquire its developer, Durata Therapeutics, for $675 million. View the DRTX premarket stock price ahead of the market session or assess the after hours quote. Durata's shares were trading Free Business profile for DURATA THERAPEUTICS INC at 200 S Wacker Dr, Chicago, IL, 60606-5811, US. 了解Durata Therapeutics, Inc. established in 2009, is a clinical development stage biopharmaceutical company addressing the growing need for new therapeutics to treat infectious diseases. Their dedication to advancing therapeutic solutions is not only impressive but also inspiring, demonstrating a rare Explore Durata Therapeutics, Inc. Food and Drug Administration Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Durata Therapeutics, Inc. - BioCentury Company Profiles for the biopharma industry Item 5. Durata's Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. 01 per share (Title of Class of Securities) 26658A107 (CUSIP Number of Class of Securities) Paul R. Durata Therapeutics Durata is a biopharmaceutical company pursuing late-stage clinical development of novel antibiotic programs. 3r0l77a, fuz, ej6, ef4w3o, hiyjy, 91lzmgoa, aelg4, tbm0l, lhcrd, pq3v,